Ensure beneficiaries have access to the latest medical technologies and remove barriers to advancing innovation across our healthcare system.

- CMS will proactively react to the evolving health care marketplace, including emerging medical technologies (e.g. drugs, biologics, medical devices), to create policies that focus on results, ensuring access to cutting-edge therapies for our beneficiaries while improving the quality of care and reducing costs.

- Areas ripe for disruption include: optimizing coverage, coding, and payment policy for new medical technologies; payment reform for antimicrobial drugs; and accelerating patient access to promising medical devices.

- CMS will ensure beneficiaries have access to the latest medical innovations and remove barriers to support unleashing innovation across our healthcare system.

- Improved access to these medical technologies will empower patients to make the best healthcare decisions for themselves.

- Recent actions include:
  - We responded to the President’s Executive Order on Protecting and Improving Medicare for Our Nation’s Seniors by streamlining the innovative medical products process by providing alternatives for new technology add-on payment (NTAP) pathway in which Breakthrough Devices are no longer required to demonstrate evidence of “substantial clinical improvement” to qualify for new technology add-on payments. This will provide additional Medicare payment for these technologies while real-world evidence is emerging, giving Medicare beneficiaries timely access to the latest innovations in treatment.
  - We increased the NTAP to 65% for all medical products to remove disincentives for the most promising new technologies
  - We are now covering the FDA-approved Chimeric Antigen Receptor T-cell, or “CAR T-cell” therapy cancer treatment that uses a patient’s own genetically modified immune cells to fight disease to treat some people with specific types of cancer.
  - We also took rapid action to combat antimicrobial resistance and secure access to life-saving new antibiotic drugs for American seniors, by removing several financial disincentives and setting policies to reduce inappropriate use.